GE Healthcare has unveiled new molecular imaging technologies to help clinicians advance quantitative care and research.
The technolgies, Discovery MI system and Discovery NM/CT 670 CZT, were showcased at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2016 in San Diego, US.
Both systems feature digital detectors that the company claims represent the next generation of molecular imaging systems.
Xeleris 4.0 is the new nuclear medicine workstation that supports Discovery NM/CT 670 CZT and other nuclear medicine systems.
The Discovery MI system will enable clinicians to diagnose and stage disease earlier, as well as better guide treatment strategies.
With the help of an expanded field-of-view (FOV), the system will enable clinicians to conduct research such as quantitative brain studies.
The system can also be used in, oncology, neurology, cardiology and other applications.
LightBurst digital detector enables the system to deliver up to two times improvement in volumetric resolution, in addition to enabling small lesion detectability.
The Discovery NM/CT 670 CZT has been developed to deliver improvements in lesion detection and image quality.
The system’s Xeleris 4.0 allows the system to be used in various quantitative applications to better diagnose and monitor diseases earlier.
Discovery NM/CT 670 CZT is claimed to be the world’s first general purpose SPECT/CT imaging system with a new digital detector supported by cadmium zinc telluride (CZT) technology.
The technology allows direct conversion of photons into a digital signal, which eliminates the signal loss and noise inherent in conventional SPECT/CT detection technology.
The system allows the doctor to carry out exams on every organ, including whole-body exams.
Image: GE Healthcare has launched new molecular imaging technologies at SNMMI 2016. Photo: courtesy of General Electric.